Characterization of human senescent cell biomarkers for clinical trials

Joshua N Farr,David G Monroe,Elizabeth J Atkinson,Mitchell N Froemming,Ming Ruan,Nathan K LeBrasseur,Sundeep Khosla

DOI: https://doi.org/10.1101/2024.11.02.24316643

2024-11-05

Abstract:There is an increasing need for blood-based biomarkers of senescent cell burden to facilitate selection of participants for clinical trials. Potential candidates include expression in peripheral blood T-cells and circulating protein concentrations of the senescence-associated secretory phenotype (SASP). is encoded by the locus, which produces six variant transcripts in humans, two of which encode homologous p16 proteins: p16 encoded by , and p16ɣ, encoded by . While distinct quantitative polymerase chain reaction primers can be designed for , primers for also measure ( ). In a recent clinical trial evaluating effects of the senolytic combination, dasatinib + quercetin (D+Q), on bone metabolism in postmenopausal women, we found that women in the highest tertile for T-cell expression of had the most robust skeletal responses to D+Q. Importantly, assessment of was more predictive of these responses than . Here, we provide a comprehensive in vitro and in vivo characterization of expression. In vitro, increased rapidly (week 1) following the induction of DNA damage, whereas increased later (week 4), consistent with the latter being more specific for an established senescent state. Further analysis of our clinical trial data identified a SASP panel in plasma that correlated with expression in T-cells and performed as well in identifying postmenopausal women with a positive skeletal response to D+Q. Collectively, our findings support that the assessment of T-cell expression may be more specific for senescence and provide further support for this assay as a biomarker for selecting participants in clinical trials of senolytic interventions. In addition, our data indicate that correlated plasma SASP markers could be used in lieu of the more technically challenging T-cell assay. Finally, the ability to identify individuals with a beneficial skeletal response to D+Q using two different measures of senescent cell burden (i.e., the T-cell assay and the SASP score) provides further support for the hypothesis that the underlying senescent cell burden dictates the clinical response to a senolytic intervention.